Commercial

Commercial
Synaptogenix shares price soars up in anticipation of positive data

Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Synaptogenix raised $12.5 M and announced Phase 2b Bryostatin-1 clinical trial update Bryostatin-1 (Protein kinase C (PKC) agonist) – Synaptogenix The net proceeds of the private placement will be used to fund […]

by Sandhya Ramalingam

Continue Reading
Commercial
BioVie gets Phase 3 ready NE3107 for Alzheimer’s with NeurMedix acquisition

Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 BioVie announced closing of acquisition of biopharma assets from privately held NeurMedix NE3107 (ERK inhibitor) – BioVie/ NeurMedix The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces […]

by Sandhya Ramalingam

Continue Reading